Atrion Co. (NASDAQ:ATRI) Director John P. Stupp, Jr. sold 277 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $711.47, for a total value of $197,077.19. Following the completion of the transaction, the director now owns 5,844 shares in the company, valued at $4,157,830.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NASDAQ:ATRI traded down $1.16 during mid-day trading on Wednesday, hitting $706.34. 6,477 shares of the company traded hands, compared to its average volume of 12,314. The firm has a market cap of $1.31 billion, a P/E ratio of 36.01 and a beta of 0.14. Atrion Co. has a 52-week low of $671.05 and a 52-week high of $948.03. The firm’s 50 day simple moving average is $768.00 and its 200 day simple moving average is $798.03.
Atrion (NASDAQ:ATRI) last announced its earnings results on Friday, November 1st. The medical instruments supplier reported $5.15 EPS for the quarter. The business had revenue of $38.88 million for the quarter. Atrion had a return on equity of 16.45% and a net margin of 23.43%.
Several large investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its holdings in shares of Atrion by 0.6% during the 2nd quarter. AQR Capital Management LLC now owns 2,677 shares of the medical instruments supplier’s stock valued at $2,283,000 after buying an additional 17 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Atrion by 10.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 322 shares of the medical instruments supplier’s stock valued at $275,000 after buying an additional 30 shares during the period. California State Teachers Retirement System increased its holdings in Atrion by 1.9% during the 3rd quarter. California State Teachers Retirement System now owns 2,246 shares of the medical instruments supplier’s stock worth $1,750,000 after purchasing an additional 42 shares during the last quarter. Pennsylvania Trust Co increased its holdings in Atrion by 0.6% during the 3rd quarter. Pennsylvania Trust Co now owns 10,329 shares of the medical instruments supplier’s stock worth $8,048,000 after purchasing an additional 65 shares during the last quarter. Finally, Krane Funds Advisors LLC purchased a new stake in Atrion during the 2nd quarter worth approximately $57,000. Institutional investors and hedge funds own 66.08% of the company’s stock.
Several brokerages recently commented on ATRI. BidaskClub downgraded Atrion from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 19th. ValuEngine upgraded Atrion from a “sell” rating to a “hold” rating in a report on Friday, November 8th.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More: Market Capitalization in the Stock Market
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.